LungLife AI (Cynvenio) Names James McCullough as Board Member

March 18, 2019

WESTLAKE VILLAGE, CA – March 18, 2019 – LungLife AI, a leader in liquid biopsy technology for cancer diagnosis and management, announced today that James McCullough has been appointed as Board member.

Mr. McCullough has leadership experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. His focus is on equity and debt capital formation, strategic development and partnerships. James is currently the CEO of Renalytix AI, PLC, an AIM listed company (AIM: RENX), which develops Artificial Intelligence enabled In-Vitro Diagnostics for kidney disease.  James’ was most recently chief executive officer of Exosome Diagnostics, a venture backed personalized medicine company developing non-invasive liquid biopsy diagnostics in cancer, sold to Bio-Techne (NASDAQ: TECH).  James is also a managing partner of Renwick Capital, LLC (“Renwick”), a management consulting firm specializing in assisting emerging healthcare technology companies with strategic planning and business execution and a co-founder of PAIGE.AI, a computational pathology spin-out from the Memorial Sloan Kettering Cancer Center.

 “The Board is pleased to welcome James and we strongly believe that his experience in both the private and public funding markets will assist LungLife AI into its next stage of development,” said Simon Raab, Chairman of LungLife AI’s Board of Directors. “The company’s Artificial Intelligence (AI) enabled diagnostic solutions are poised to transform liquid biopsy-based technologies and James’ experience in this area will be invaluable.”

About LungLife AI, Inc.

LungLife AI is focused on the development of cancer diagnostic solutions, particularly in lung disease, recognizing the need to substantially improve patient outcomes. The company’s tests span all stages of cancer and are designed to deliver actionable information to clinicians via minimally invasive blood draw. LungLife AI is based in Thousand Oaks, California. For more information, please visit

LiquidBiopsy® is a registered trademark of LungLife AI, Inc.

© 2020 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.